Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s279. https://doi.org/10.25251/skin.7.supp.279